Ronald C. Renaud

Ron has served as Translate Bio’s chief executive officer since 2014. Formerly, Ron was at Idenix Pharmaceuticals (2007-2014), where he served as chief financial officer, chief business officer and finally, president and chief executive officer. Under his leadership, Idenix refocused its drug-discovery and development efforts and streamlined operations to better enable cross-functional collaboration and employee engagement, which culminated in its acquisition by Merck for $3.85 billion in August 2014. Prior to joining Idenix, Ron served as senior vice president and chief financial officer of Keryx Biopharmaceuticals. Before joining Keryx, Ron was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Ron holds a BA from St. Anselm College and an MBA from the Marshall School of Business at the University of Southern California. In addition to serving on the Translate Bio board of directors, Ron is a board member of Akebia Therapeutics, Chimerix and Axial Biotherapeutics. Ron also serves on the Board of Overseers at Newton-Wellesley Hospital and the Board of Trustees at Saint Anselm College.